Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?

J Thorac Oncol. 2019 Feb;14(2):e38-e40. doi: 10.1016/j.jtho.2018.10.154.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / complications*
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / secondary
  • Adult
  • Anaplastic Lymphoma Kinase / genetics
  • Antineoplastic Agents / adverse effects*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / secondary
  • Fatal Outcome
  • Female
  • Humans
  • Lung Neoplasms / complications*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Organophosphorus Compounds / adverse effects*
  • Pulmonary Arterial Hypertension / etiology*
  • Pyrimidines / adverse effects*

Substances

  • Antineoplastic Agents
  • Organophosphorus Compounds
  • Pyrimidines
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • brigatinib